GlaxoSmithKline’s ViiV Healthcare aims to shift HIV daily pill thinking in first DTC ads
For as long as there have been HIV medicines, the only options for patients have been daily pills — until this year that is. GlaxoSmithKline’s ViiV Healthcare approval for long-acting injectable Cabenuva in January marked a sudden change.
Instead of people with HIV taking daily pills — a habit even reinforced in pop culture in film and other fictional depictions — there’s now a once-a-month injection option.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.